Revision of effective treatment based on non-small cell lung cancer MDM۲-TP۵۳ By CRISPR/CAS۹

Lung cancer is the second most common cancer and the main cause of cancer deaths. Treatment trends for non-small cell lung cancer (NSCLC) which is ۸۰ to ۸۵ percent of all Cases of cancer was performed through surgery, Chemotherapy, Radiation therapy but after the discovery of CRISPR/CAS۹ as a strategy of short palindromic repeats a cluster by editing genes that lead to a general or targeted functional disorder is a different approach in treatment NSCLC like the detection of cell survival genes, Inhibition of induction of epigenetic changes, Genome screening offers. for example CRISPER/CAS۹ identified Oncogene MDM۲ as a potential therapeutic target with genetic inhibition and mutant gene regulation TP۵۳ , which is a tumor suppressor gene, decreased cell proliferation and disrupted tumor growth. Also with an inhibitor MDM۲ RG۷۳۸۸ induce Cell cycle and apoptosis in several cell lines NSCLC . Currently, clinical investigation of anticancer effect RG۷۳۸۸ in several Solid and hematological tumor in progress and genetic status TP۵۳ for efficacy MDM۲ inhibitory with a number of Preclinical efficacy and tolerability studies in vivo also been confirmed and It was consistent with previous study it is not yet clear if this is an effective treatment for NSCLC or no. Therefore, the purpose of this review article is the recent advances in the treatment of lung cancer (NSCLC ) , such as the therapeutic goal MDM۲-TP۵۳, Based on development CRISPR/CAS۹ technique , which can replace permanent treatment in future researches on new lung cancer treatments due to its many benefits.

کلیدواژه ها:

CRISPR/CAS۹ ، MDM۲ ، NSCLC